Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Dombi

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
Neuro-Oncology Advances|September 17, 2020
The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromasSadhana Jackson, Eva H Baker, Andrea M Gross, et al.
The Laryngoscope|December 30, 2022
Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform NeurofibromasVictoria Idowu, Julie Christensen, Andrea M Gross, et al.
Neuro-Oncology|February 7, 2018
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumorsChristine S Higham, Eva Dombi, Aljosja Rogiers, et al.
Endocrine-Related Cancer|December 11, 2025
The Prostate is a Common Site of Disease in Patients with MEN2B and Medullary Thyroid CarcinomaIra L Kraft, Srivandana Akshintala, Andrea Gross, et al.
Neuro-Oncology|October 16, 2014
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Brigitte C Widemann, Pamela Wolters, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
A molecular basis for neurofibroma-associated skeletal manifestations in NF1Yun Ma, Andrea M Gross, Eva Dombi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsElizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2023
Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor ShrinkageMark Jackson, Niousha Ahmari, Jianqiang Wu, et al.
Neurology|July 7, 2021
Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based AssessmentShivani Ahlawat, K Ina Ly, Laura M Fayad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform NeurofibromasLauren H Boal, John Glod, Melissa Spencer, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Neuro-Oncology Advances|September 17, 2020
The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromasSadhana Jackson, Eva H Baker, Andrea M Gross, et al.
The Laryngoscope|December 30, 2022
Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform NeurofibromasVictoria Idowu, Julie Christensen, Andrea M Gross, et al.
Neuro-Oncology|February 7, 2018
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumorsChristine S Higham, Eva Dombi, Aljosja Rogiers, et al.
Endocrine-Related Cancer|December 11, 2025
The Prostate is a Common Site of Disease in Patients with MEN2B and Medullary Thyroid CarcinomaIra L Kraft, Srivandana Akshintala, Andrea Gross, et al.
Neuro-Oncology|October 16, 2014
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Brigitte C Widemann, Pamela Wolters, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
A molecular basis for neurofibroma-associated skeletal manifestations in NF1Yun Ma, Andrea M Gross, Eva Dombi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsElizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2023
Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor ShrinkageMark Jackson, Niousha Ahmari, Jianqiang Wu, et al.
Neurology|July 7, 2021
Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based AssessmentShivani Ahlawat, K Ina Ly, Laura M Fayad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform NeurofibromasLauren H Boal, John Glod, Melissa Spencer, et al.
Pageof 10